14735-70-7

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
3-AZA-TRICYCLO[4.2.1.0(2,5)]NON-7-EN-4-ONE is used as a potential precursor for the development of new drugs and therapeutic agents due to its unique structure and potential biological activity. Its heterocyclic nature and tricyclic ring system may contribute to the discovery of novel pharmacological properties and mechanisms of action.
Used in Organic Chemistry Research:
In the field of organic chemistry, 3-AZA-TRICYCLO[4.2.1.0(2,5)]NON-7-EN-4-ONE is used as a subject of study for its complex ring system and ketone functional group. Researchers may explore its synthesis pathways, reactivity, and potential applications in the formation of other complex organic molecules, contributing to the advancement of synthetic methodologies and the understanding of molecular interactions.
Used in Chemical Synthesis:
3-AZA-TRICYCLO[4.2.1.0(2,5)]NON-7-EN-4-ONE is utilized as a key intermediate in the synthesis of various organic compounds, particularly those with complex ring systems. Its unique structure allows for the development of novel synthetic routes and the creation of new chemical entities with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C8H9NO/c10-8-6-4-1-2-5(3-4)7(6)9-8/h1-2,4-7H,3H2,(H,9,10)/t4-,5+,6+,7-/m0/s1

Upstream product

• 121-46-0 bicyclo[2.2.1]hepta-2,5-diene 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 14805-30-2 4-oxo-(1rC⁹,2tH,5tH,6cC⁹)-3-aza-tricyclo[4.2.1.0^2,5]non-7-ene-3-sulfonyl chloride 
• 121-46-0 bicyclo[2.2.1]hepta-2,5-diene 

Downstream Products

• 92511-32-5 3-exo-aminobicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid 
• 91813-47-7 (1R,2R,3S,4S)-3-(4-Methyl-benzoylamino)-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid 
• 91813-48-8 (1R,2R,3S,4S)-3-(4-Chloro-benzoylamino)-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid 
• 91813-49-9 (1S,2S,3R,4R)-3-(3,4-Dichloro-benzoylamino)-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid 
• 79439-38-6 (1S,2S,3R,4R)-3-Benzoylamino-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid 
• 91813-50-2 (1R,2R,7S,8S)-4-Phenyl-5-oxa-3-aza-tricyclo[6.2.1.0^2,7]undeca-3,9-dien-6-one 
• 91813-51-3 (1R,2R,7S,8S)-4-p-Tolyl-5-oxa-3-aza-tricyclo[6.2.1.0^2,7]undeca-3,9-dien-6-one 
• 91813-52-4 (1R,2R,7S,8S)-4-(4-Chloro-phenyl)-5-oxa-3-aza-tricyclo[6.2.1.0^2,7]undeca-3,9-dien-6-one 
• 91813-53-5 (1S,2S,7R,8R)-4-(3,4-Dichloro-phenyl)-5-oxa-3-aza-tricyclo[6.2.1.0^2,7]undeca-3,9-dien-6-one 
• 1190392-23-4 methyl [6(S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]]pyrimidine-6-carboxylate 
• 1190709-67-1 methyl (7S)-9-oxo-3,8-diazatetracyclo[9.2.1.0(2,10).0(4,8)]tetradeca-3,12-diene-7-carboxylate 
• 113094-20-5 3-(p-chlorophenyl)carbamoylaza-4-oxotetracyclo<4.2.1.0>non-7-ene 
• 33643-94-6 4-oxo-2-phenyl-3,4-dihydropyrimidine 
• 924272-78-6 (1S,2S,5R,6R)-exo-3-azatricyclo[4.2.1.0(2,5)]non-7-en-4-one 

Relevant academic research and scientific papers

Diversity-oriented Functionalization of Cyclodienes Through Selective Cycloaddition/Ring-opening/Cross-metathesis Protocols; Transformation of a “Flatland” into Three-dimensional Scaffolds With Stereo- and Regiocontrol

This article presents selective transformations of some readily available cyclodienes through simple chemical procedures into novel functionalized small-molecular entities. The syntheses hereby described involved selective cycloadditions, followed by ring

Ring-opening metathesis of n-alkenyl β-lactams?

– We have synthesized a new class of N-alkenylated β-lactam derivatives and studied their metathetic behavior. Here, ring-opening metathesis is more favorable than ring-rearrangement metathesis. Molecular modelling studies revealed that the orientation of two olefinic moieties of β-lactam derivatives are far apart and therefore ring-rearrangement metathesis did not occur and ring-opening metathesis is only feasible.

PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES

The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.

Development and scale-up of an optimized route to the ALK inhibitor CEP-28122

Evolution of the process strategies to prepare CEP-28122, an anaplastic lymphoma kinase (ALK) inhibitor, is presented. The initial medicinal chemistry route, used for the preparation of key supplies for biological screening, is reviewed. In addition, the

[1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS

The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Double retro Diels-Alder reaction applied for preparation of a pyrimido[1,2-b]pyridazine

Boiling diendo- or diexo-2-aminobicyclo[2.2.1]hept-5-ene-3- carbohydrazides 1 with 3-aroylnorbornenecarboxylic acid 2 in toluene yielded the pyrimido[1,2-b]pyridazine 4 directly in a double retro Diels-Alder process. Similarly, the reaction of anthranilic hydrazide 5 and 2 furnished the tricyclic benzo-fused analogue 7 via a single cycloreversion. The principle of the new method applied: the reactants were built up on cyclopentadienes and the dienes were cleaved by heating after condensation to furnish hetero bicyclic compound.

STEREOCHEMICAL STUDIES -- 79 SYNTHESIS AND KINETIC STUDY ON THE RETRODIENE DECOMPOSITION OF NORBORNENE-CONDENSED 1,3-OXAZIN-4-ONES

The cis-exo-amino acid 3 with norbornene skeleton was converted into 2-aryl-cis-exo-1,3-oxazin-4-ones 5a-d.These compounds, similarly to the diendo isomers 1a-d studied by us earlier, undergo retrodiene decomposition under mild conditions to give 2-aryl-6